Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price reduced by analysts at Maxim Group to $1.50 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s price target suggests a potential upside of 284.52% from the stock’s current price. Several other analysts have also recently issued reports on the […]
Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXTW – Get Rating) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 89,500 shares, a growth of 1,981.4% from the April 30th total of 4,300 shares. Based on an average daily volume of 273,300 shares, the short-interest ratio […]
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price cut by equities researchers at Needham & Company LLC to $3.00 in a research note issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. A number of other equities analysts also recently issued reports on the stock. […]
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price decreased by stock analysts at Truist Financial from $7.00 to $3.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Truist Financial’s target price indicates a potential upside of 458.24% from the stock’s previous close. Other research analysts have also […]
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.